PharmaCyte Biotech (OTCMKTS:PMCBD) Shares Down 9.3% – Should You Sell?

Shares of PharmaCyte Biotech Inc (OTCMKTS:PMCBD) traded down 9.3% on Monday . The stock traded as low as $0.6922 and last traded at $0.7080. 241,444 shares were traded during mid-day trading, an increase of 2,634% from the average session volume of 8,831 shares. The stock had previously closed at $0.7802.

PharmaCyte Biotech Trading Down 9.3%

The business has a 50 day simple moving average of $0.75 and a two-hundred day simple moving average of $0.85.

About PharmaCyte Biotech

PharmaCyte Biotech is a clinical‐stage biotechnology company focused on the development and commercialization of targeted cellular therapies for cancer and diabetes. The company’s core technology, Cell-in-a-Box, encapsulates live, genetically modified cells within a proprietary cellulose‐based polymer matrix. This platform is designed to deliver therapeutic agents directly at tumor sites or within the pancreas, with the goal of maximizing efficacy while minimizing systemic side effects.

In its lead oncology program, PharmaCyte is conducting clinical trials for advanced pancreatic cancer, combining Cell-in-a-Box–encased cells with the prodrug ifosfamide.